Last reviewed · How we verify
intransal insulin
intransal insulin is a Small molecule drug developed by German Diabetes Center. It is currently FDA-approved. Also known as: intranasal insulin.
Intransal insulin, developed by the German Diabetes Center, is a marketed product designed for the treatment of diabetes through nasal administration. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk lies in the potential for increased competition once the patent expires, which could impact revenue and market share.
At a glance
| Generic name | intransal insulin |
|---|---|
| Also known as | intranasal insulin |
| Sponsor | German Diabetes Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect? (PHASE4)
- The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism (PHASE4)
- Investigation of the Safety of Intranasal Glulisine in Down Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intransal insulin CI brief — competitive landscape report
- intransal insulin updates RSS · CI watch RSS
- German Diabetes Center portfolio CI
Frequently asked questions about intransal insulin
What is intransal insulin?
Who makes intransal insulin?
Is intransal insulin also known as anything else?
What development phase is intransal insulin in?
Related
- Manufacturer: German Diabetes Center — full pipeline
- Also known as: intranasal insulin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing